bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Authors: Sparano Joseph A. , Goldstein Lori J. , Childs Barrett H. , Shak Steven , Brassard Diana , Badve Sunil , Baehner Frederick L. , Bugarini Roberto , Rowley Steve , Perez Edith A. , Shulman Lawrence N. , Martino Silvana , Davidson Nancy E. , Kenny Paraic A. , Sledge George W. , Gray Robert
Published: April 2023

PDF file - 21K, Triple negative higher expression.
Supplementary Table 3 from Opposing Effects of Runx2 and Estradiol on Breast Cancer Cell Proliferation: In Vitro Identification of Reciprocally Regulated Gene Signature Related to Clinical Letrozole Responsiveness
Authors: Chimge Nyam-Osor , Baniwal Sanjeev K. , Luo Jingqin , Coetzee Simon , Khalid Omar , Berman Benjamin P. , Tripathy Debu , Ellis Matthew J. , Frenkel Baruch
Published: April 2023

PDF file - 1.3MB, Complete list of genes interrogated by BeadChip microarrays and fold changes in array comparisons.
Supplementary Figure Legends 1-7 from MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
Authors: Migliore Cristina , Martin Valentina , Leoni Vera P. , Restivo Angelo , Atzori Luigi , Petrelli Annalisa , Isella Claudio , Zorcolo Luigi , Sarotto Ivana , Casula Giuseppe , Comoglio Paolo M. , Columbano Amedeo , Giordano Silvia
Published: April 2023

PDF file - 279K
Supplementary Figure 6 from MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
Authors: Migliore Cristina , Martin Valentina , Leoni Vera P. , Restivo Angelo , Atzori Luigi , Petrelli Annalisa , Isella Claudio , Zorcolo Luigi , Sarotto Ivana , Casula Giuseppe , Comoglio Paolo M. , Columbano Amedeo , Giordano Silvia
Published: April 2023

PDF file - 7.1MB
Supplementary Figure 2 from Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Authors: Flaherty Keith T. , LoRusso Patricia M. , DeMichele Angela , Abramson Vandana G. , Courtney Rachel , Randolph Sophia S. , Shaik M. Naveed , Wilner Keith D. , O'Dwyer Peter J. , Schwartz Gary K.
Published: April 2023

PDF file - 330K
Supplementary Figure 2 from MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
Authors: Migliore Cristina , Martin Valentina , Leoni Vera P. , Restivo Angelo , Atzori Luigi , Petrelli Annalisa , Isella Claudio , Zorcolo Luigi , Sarotto Ivana , Casula Giuseppe , Comoglio Paolo M. , Columbano Amedeo , Giordano Silvia
Published: April 2023

PDF file - 225K
Supplementary Table 7 from Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Authors: Hong Seung-Mo , Omura Noriyuki , Vincent Audrey , Li Ang , Knight Spencer , Yu Jun , Hruban Ralph H. , Goggins Michael
Published: April 2023

PDF file - 70K
Supplementary Figure 2 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Authors: Fraser Michael , Zhao Helen , Luoto Kaisa R. , Lundin Cecilia , Coackley Carla , Chan Norman , Joshua Anthony M. , Bismar Tarek A. , Evans Andrew , Helleday Thomas , Bristow Robert G.
Published: April 2023

PDF file - 31K
Supplementary Figure 4 from Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer
Authors: Halle Cathinka , Lando Malin , Svendsrud Debbie Hege , Clancy Trevor , Holden Marit , Sundfør Kolbein , Kristensen Gunnar B. , Holm Ruth , Lyng Heidi
Published: April 2023

PDF file - 141K
Supplementary Figure 4 from Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Authors: Hong Seung-Mo , Omura Noriyuki , Vincent Audrey , Li Ang , Knight Spencer , Yu Jun , Hruban Ralph H. , Goggins Michael
Published: April 2023

PDF file - 321K
Supplementary Figure 3 from Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Authors: Hong Seung-Mo , Omura Noriyuki , Vincent Audrey , Li Ang , Knight Spencer , Yu Jun , Hruban Ralph H. , Goggins Michael
Published: April 2023

PDF file - 33K
Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Authors: Brown Jennifer R. , Hanna Megan , Tesar Bethany , Werner Lillian , Pochet Nathalie , Asara John M. , Wang Yaoyu E. , dal Cin Paola , Fernandes Stacey M. , Thompson Christina , MacConaill Laura , Wu Catherine J. , Van de Peer Yves , Correll Mick , Regev Aviv , Neuberg Donna , Freedman Arnold S.
Published: April 2023

PDF file, 449KB.
Supplementary Figures 1-2, Table 1 from Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma
Authors: Fang Hua , Harned Theresa M. , Kalous Ondrej , Maldonado Vanessa , DeClerck Yves A. , Reynolds C. Patrick
Published: April 2023

PDF file - 160K
Supplementary Methods, Figures Legends 1-4, Table 1 from To DNA or not to DNA? That Is the Question, When It Comes to Molecular Subtyping for the Clinic!
Authors: Smeets Serge J. , Harjes Ulrike , van Wieringen Wessel N. , Sie Daoud , Brakenhoff Ruud H. , Meijer Gerrit A. , Ylstra Bauke
Published: April 2023

PDF file - 91K
Table 6 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Authors: Spindler Karen-Lise Garm , Pallisgaard Niels , Vogelius Ivan , Jakobsen Anders
Published: April 2023

PDF file - 49K
Figure 5 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Authors: Spindler Karen-Lise Garm , Pallisgaard Niels , Vogelius Ivan , Jakobsen Anders
Published: April 2023

PDF file - 81K
Figure 3 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Authors: Spindler Karen-Lise Garm , Pallisgaard Niels , Vogelius Ivan , Jakobsen Anders
Published: April 2023

PDF file - 40K
Supplementary Methods, Figures 1-7, Table 1 from Evaluation of Deuterated 18F- and 11C-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography
Authors: Witney Timothy H. , Alam Israt S. , Turton David R. , Smith Graham , Carroll Laurence , Brickute Diana , Twyman Frazer J. , Nguyen Quang-Dé , Tomasi Giampaolo , Awais Ramla O. , Aboagye Eric O.
Published: April 2023

PDF file - 474K
Supplementary Materials and Methods from Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
Authors: Daud Adil I. , Krishnamurthi Smitha S. , Saleh Mansoor N. , Gitlitz Barbara J. , Borad Mitesh J. , Gold Philip J. , Chiorean Elena G. , Springett Gregory M. , Abbas Richat , Agarwal Shefali , Bardy-Bouxin Nathalie , Hsyu Poe-Hirr , Leip Eric , Turnbull Kathleen , Zacharchuk Charles , Messersmith Wells A.
Published: April 2023

PDF file - 88K
Supplementary Tables 1 - 4 from Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters
Authors: Nishida Naohiro , Nagahara Makoto , Sato Tetsuya , Mimori Koshi , Sudo Tomoya , Tanaka Fumiaki , Shibata Kohei , Ishii Hideshi , Sugihara Kenichi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF file, 69KB, Supplementary Table S: Correlation coefficient of array signals in the components of the miR-17-92a and miR-25-106b clusters; Supplementary Table S2; Supplementary Table. S3: Downregulated microRNAs in colorectal cancer stromal tissue compared with normal stromal tissue; Supplementary Table. S4A: Upregulated microRNAs in colorectal cancer stromal tissue compared with cancer epithelial tissue; Supplementary Table. S4B: Downregulated microRNAs in colorectal cancer stromal tissue compared with cancer epithelial tissue.
Supplementary Figure 1 from Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
Authors: Daud Adil I. , Krishnamurthi Smitha S. , Saleh Mansoor N. , Gitlitz Barbara J. , Borad Mitesh J. , Gold Philip J. , Chiorean Elena G. , Springett Gregory M. , Abbas Richat , Agarwal Shefali , Bardy-Bouxin Nathalie , Hsyu Poe-Hirr , Leip Eric , Turnbull Kathleen , Zacharchuk Charles , Messersmith Wells A.
Published: April 2023

PDF file - 89K
Supplementary Figure 1B from Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters
Authors: Nishida Naohiro , Nagahara Makoto , Sato Tetsuya , Mimori Koshi , Sudo Tomoya , Tanaka Fumiaki , Shibata Kohei , Ishii Hideshi , Sugihara Kenichi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF file, 87KB, Tissue section stained with hematoxylin and eosin before (left) and after (right) laser microdissection in six representative samples of colorectal cancer. (Part II)
Supplementary Figure 1A from Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters
Authors: Nishida Naohiro , Nagahara Makoto , Sato Tetsuya , Mimori Koshi , Sudo Tomoya , Tanaka Fumiaki , Shibata Kohei , Ishii Hideshi , Sugihara Kenichi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF file, 84KB, Tissue section stained with hematoxylin and eosin before (left) and after (right) laser microdissection in six representative samples of colorectal cancer.
Supplementary Figure Legends 1-2 from BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
Authors: Hong David S. , Vence Luis , Falchook Gerald , Radvanyi Laszlo G. , Liu Chengwen , Goodman Vicki , Legos Jeffery J. , Blackman Sam , Scarmadio Antonio , Kurzrock Razelle , Lizee Gregory , Hwu Patrick
Published: April 2023

PDF file - 62K
Supplementary Tables 1 - 5 from Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients
Authors: Lin Moubin , Gu Jian , Eng Cathy , Ellis Lee M. , Hildebrandt Michelle A. , Lin Jie , Huang Maosheng , Calin George A. , Wang Dingzhi , DuBois Raymond N. , Hawk Ernest T. , Wu Xifeng
Published: April 2023

PDF file, 105KB.
Supplementary Figure 2 from BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
Authors: Hong David S. , Vence Luis , Falchook Gerald , Radvanyi Laszlo G. , Liu Chengwen , Goodman Vicki , Legos Jeffery J. , Blackman Sam , Scarmadio Antonio , Kurzrock Razelle , Lizee Gregory , Hwu Patrick
Published: April 2023

PDF file - 145K
Supplementary Data from Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres
Authors: Sciuscio Davide , Diserens Annie-Claire , van Dommelen Kristof , Martinet Danielle , Jones Greg , Janzer Robert-Charles , Pollo Claudio , Hamou Marie-France , Kaina Bernd , Stupp Roger , Levivier Marc , Hegi Monika E.
Published: April 2023

Supplementary Figures S1-S6; Supplementary Table S1.
Supplementary Figure 5 from Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Authors: Tromp Jacqueline M. , Geest Christian R. , Breij Esther C.W. , Elias Judith A. , van Laar Jacoline , Luijks Dieuwertje M. , Kater Arnon P. , Beaumont Tim , van Oers Marinus H.J. , Eldering Eric
Published: April 2023

PDF file - 866K, CLL cells were stimulated with CD40L for 48 hrs. After detachment, cells were incubated with 10 �M or 100 �M fludarabine � Q-VD (12,5 �M), � NAC (5mM). Protein lysates were probed for Noxa, Mcl-1 and �-actin.
Supplementary Figure 4 from Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Authors: Tromp Jacqueline M. , Geest Christian R. , Breij Esther C.W. , Elias Judith A. , van Laar Jacoline , Luijks Dieuwertje M. , Kater Arnon P. , Beaumont Tim , van Oers Marinus H.J. , Eldering Eric
Published: April 2023

PDF file - 732K, A. CLL cells were stimulated with CD40L for 72 hrs. After detachment, cells were incubated with 0.1 �M of ABT-737. Protein lysates were probed for Mcl-1, Bfl-1, Noxa and �-actin. B. Densitometric analysis of Mcl-1/ �-actin levels of fourteen CLL samples is shown. Bars represent the mean � SEM, *** P < .001.
Supplementary Table 1 from Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Authors: Lucas Keryn M. , Mohana-Kumaran Nethia , Lau Diana , Zhang Xu Dong , Hersey Peter , Huang David C. , Weninger Wolfgang , Haass Nikolas K. , Allen John D.
Published: April 2023

PDF file - 46K, Sensitivity of NOXA-transduced melanoma cells to DNA-damaging agents.
Supplementary Figure 1 from Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Authors: Tromp Jacqueline M. , Geest Christian R. , Breij Esther C.W. , Elias Judith A. , van Laar Jacoline , Luijks Dieuwertje M. , Kater Arnon P. , Beaumont Tim , van Oers Marinus H.J. , Eldering Eric
Published: April 2023

PDF file - 986K, A. ABT-737 resistant CLL cells were stimulated with CD40L for 72 hours (n=4). The black line shows apoptosis levels from CLL cells detached from the feeder layer and subsequently treated with different concentrations of ABT-737 (0.001-10 �M). CLL cells treated with ABT-737 in the presence of CD40-expressing feeder cells are depicted in gray. B. ABT-737 sensitive CD40-stimulated CLL cells treated with ABT-737 after detachment from feeder cells (black line) and while continuously in contact with CD40-expressing feeder cells (gray line) (n=5).
Supplementary Data from An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma
Authors: Asundi Jyoti , Reed Chae , Arca Jennifer , McCutcheon Krista , Ferrando Ronald , Clark Suzanna , Luis Elizabeth , Tien Janet , Firestein Ron , Polakis Paul
Published: April 2023

Supplementary Figures S1-S6.
CCR Translation for This Article from Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
Authors: Beji Abdelhamid , Horst David , Engel Jutta , Kirchner Thomas , Ullrich Axel
Published: April 2023

CCR Translation for This Article from Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
Supplementary Figure 3 from Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Authors: Lucas Keryn M. , Mohana-Kumaran Nethia , Lau Diana , Zhang Xu Dong , Hersey Peter , Huang David C. , Weninger Wolfgang , Haass Nikolas K. , Allen John D.
Published: April 2023

PDF file - 3.7MB, Spheroids derived from untransfected or NOXA-overexpressing MM200 or C8161 melanoma cells.
Supplementary Table 1-2 from Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Authors: Lee Edmund C. , Fitzgerald Michael , Bannerman Bret , Donelan Jill , Bano Kristen , Terkelsen Jennifer , Bradley Daniel P. , Subakan Ozlem , Silva Matthew D. , Liu Ray , Pickard Michael , Li Zhi , Tayber Olga , Li Ping , Hales Paul , Carsillo Mary , Neppalli Vishala T. , Berger Allison J. , Kupperman Erik , Manfredi Mark , Bolen Joseph B. , Van Ness Brian , Janz Siegfried
Published: April 2023

PDF file - 108K
Supplementary Table 11 from IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Authors: Gorovets Daniel , Kannan Kasthuri , Shen Ronglai , Kastenhuber Edward R. , Islamdoust Nasrin , Campos Carl , Pentsova Elena , Heguy Adriana , Jhanwar Suresh C. , Mellinghoff Ingo K. , Chan Timothy A. , Huse Jason T.
Published: April 2023

PDF file, 82KB, Histopathological features of diffuse astrocytic gliomas (MSKCC sample set) stratified by molecular subclass, WHO grade, and primary/recurrent tumor status. P values are shown. Pro: prominent (characterizing >50% of tumor), Pre: present, Ab: absent, NB: neuroblastic, EPL: early progenitor-like, PG: pre-GBM.
Supplementary Table 10 from IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Authors: Gorovets Daniel , Kannan Kasthuri , Shen Ronglai , Kastenhuber Edward R. , Islamdoust Nasrin , Campos Carl , Pentsova Elena , Heguy Adriana , Jhanwar Suresh C. , Mellinghoff Ingo K. , Chan Timothy A. , Huse Jason T.
Published: April 2023

PDF file, 91KB, Demographic and molecular features of diffuse astrocytic gliomas (MSKCC sample set) stratified by primary/recurrent tumor status. P values are shown. Mt: mutant, Wt: wild-type, IHC: immunohistochemistry, unkn: unknown, FISH: fluorescence in-situ hybridization, NB: neuroblastic, EPL: early progenitorlike, PG: pre-GBM.
Supplementary Figures 1-2, Tables 1-2 from CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
Authors: Aoe Keisuke , Amatya Vishwa Jeet , Fujimoto Nobukazu , Ohnuma Kei , Hosono Osamu , Hiraki Akio , Fujii Masanori , Yamada Taketo , Dang Nam H. , Takeshima Yukio , Inai Kouki , Kishimoto Takumi , Morimoto Chikao
Published: April 2023

PDF file - 171K
Supplementary Figure 2 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
Authors: Finegold David N. , Baty Catherine J. , Knickelbein Kelly Z. , Perschke Shelley , Noon Sarah E. , Campbell Diana , Karlsson Jenny M. , Huang Diana , Kimak Mark A. , Lawrence Elizabeth C. , Feingold Eleanor , Meriney Stephen D. , Brufsky Adam M. , Ferrell Robert E.
Published: April 2023

PDF file - 154K, Mutation chromatograms.
Supplementary Figure 2 from IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Authors: Gorovets Daniel , Kannan Kasthuri , Shen Ronglai , Kastenhuber Edward R. , Islamdoust Nasrin , Campos Carl , Pentsova Elena , Heguy Adriana , Jhanwar Suresh C. , Mellinghoff Ingo K. , Chan Timothy A. , Huse Jason T.
Published: April 2023

PDF file, 345KB, Representative immunohistochemical stains and scoring. All photomicrographs were taken at 400X magnification. A, p53 immunopositivity required nuclear staining in >30% of tumor cells. B, PDGFRA immunopositivity required detectable staining, and was frequently seen in only a subset of tumor cells, particularly in IDH mt tumors. C, Strong p-PRAS40 immunostaining required robust signal in the majority of tumor cells. D, IDH R132H immunopositivity required detectable staining.
Supplementary Figure 1 from IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Authors: Gorovets Daniel , Kannan Kasthuri , Shen Ronglai , Kastenhuber Edward R. , Islamdoust Nasrin , Campos Carl , Pentsova Elena , Heguy Adriana , Jhanwar Suresh C. , Mellinghoff Ingo K. , Chan Timothy A. , Huse Jason T.
Published: April 2023

PDF file, 114KB, Kaplan-Meier curves showing overall survival for recurrent MSKCC diffuse astrocytic gliomas stratified by WHO grade and prior treatment modality (Surg: surgery only; Surg + Adj: surgery plus adjuvant radiation therapy and/or chemotherapy). Sample sizes are in parentheses. P=0.083 for WHO II tumors and P=0.363 for WHO III tumors.
Supplementary Figure Legend from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Authors: Scotto Luigi , Kruithof-de Julio Marianna , Paoluzzi Luca , Kalac Matko , Marchi Enrica , Buitrago Jairo Baquero , Amengual Jennifer , Shen Michael M. , O'Connor Owen A.
Published: April 2023

PDF file, 43KB.
Supplementary Figures 1-17 from Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
Authors: DeLay Michael , Jahangiri Arman , Carbonell W. Shawn , Hu Yu-Long , Tsao Sean , Tom Maxwell Wing , Paquette Jesse , Tokuyasu Taku A. , Aghi Manish K.
Published: April 2023

PDF file, 2979KB, This is a PDF file containing Supplementary Figures S1-S17 on 17 pages, with the figure legend on the same page as each Supplementary Figure. These Supplementary Figures are cited in the text of the manuscript.
Supplementary Figure 2 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Authors: Scotto Luigi , Kruithof-de Julio Marianna , Paoluzzi Luca , Kalac Matko , Marchi Enrica , Buitrago Jairo Baquero , Amengual Jennifer , Shen Michael M. , O'Connor Owen A.
Published: April 2023

PDF file, 1117KB, Histologic analysis of CD19cherryluciferase transgenic mice. Sections are from (a-c) spleen and (b-d) lymph nodes from a mouse of three months of age. Hematoxylin and eosin (a-b) X20 (c-d) or X40.
Supplementary Figure 1 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Authors: Scotto Luigi , Kruithof-de Julio Marianna , Paoluzzi Luca , Kalac Matko , Marchi Enrica , Buitrago Jairo Baquero , Amengual Jennifer , Shen Michael M. , O'Connor Owen A.
Published: April 2023

PDF file, 432KB, PCR genotyping analysis of CD19cherryluciferase transgenic founders. PCR products of the targeted and wild type alleles of the CD19 locus in two transgenic founders. The PCR conditions for the left arm insertion were: 95{degree sign}C for 5 min; followed by 35 cycles of 95{degree sign}C for 30 sec, 68{degree sign}C for 30 sec, and 68{degree sign}C for 2 min and ending with 68{degree sign}C for 7 min. The PCR conditions for the right arm insertion were: 95{degree sign}C for 5 min; followed by 35 cycles of 95{degree sign}C for 30 sec, 68{degree sign}C for 30 sec, and 68{degree sign}C for 5 min and ending with 68{degree sign}C for 7 min.
Supplementary Table 6 from Global Methylation Profiling for Risk Prediction of Prostate Cancer
Authors: Mahapatra Saswati , Klee Eric W. , Young Charles Y.F. , Sun Zhifu , Jimenez Rafael E. , Klee George G. , Tindall Donald J. , Donkena Krishna Vanaja
Published: April 2023

PDF file - 70K, Significance of PTGS2 methylation in different groups of prostate cancer tissues
Supplementary Table 4C from Global Methylation Profiling for Risk Prediction of Prostate Cancer
Authors: Mahapatra Saswati , Klee Eric W. , Young Charles Y.F. , Sun Zhifu , Jimenez Rafael E. , Klee George G. , Tindall Donald J. , Donkena Krishna Vanaja
Published: April 2023

PDF file - 111K, Significance of methylation in prostate cancer tissue samples from 4 microarrays with the batch effect
Supplementary Table 4A from Global Methylation Profiling for Risk Prediction of Prostate Cancer
Authors: Mahapatra Saswati , Klee Eric W. , Young Charles Y.F. , Sun Zhifu , Jimenez Rafael E. , Klee George G. , Tindall Donald J. , Donkena Krishna Vanaja
Published: April 2023

PDF file - 269K, Significance of methylation in prostate cancer tissue samples from 4 microarrays with the batch effect
Supplementary Figure 2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Authors: Davies Michael A. , Fox Patricia S. , Papadopoulos Nicholas E. , Bedikian Agop Y. , Hwu Wen-Jen , Lazar Alexander J. , Prieto Victor G. , Culotta Kirk S. , Madden Timothy L. , Xu Quanyun , Huang Sha , Deng Wanleng , Ng Chaan S. , Gupta Sanjay , Liu Wenbin , Dancey Janet E. , Wright John J. , Bassett Roland L. , Hwu Patrick , Kim Kevin B.
Published: April 2023

PDF file - 70K
Supplementary Table 1B from Global Methylation Profiling for Risk Prediction of Prostate Cancer
Authors: Mahapatra Saswati , Klee Eric W. , Young Charles Y.F. , Sun Zhifu , Jimenez Rafael E. , Klee George G. , Tindall Donald J. , Donkena Krishna Vanaja
Published: April 2023

PDF file - 270K, Significantly methylated genes in prostate cancer tissues from the binary group comparisons
Supplementary Table 2 from Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Authors: Landreville Solange , Agapova Olga A. , Matatall Katie A. , Kneass Zachary T. , Onken Michael D. , Lee Ryan S. , Bowcock Anne M. , Harbour J. William
Published: April 2023

PDF file - 40K
Supplementary Figure 3 from Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Authors: Landreville Solange , Agapova Olga A. , Matatall Katie A. , Kneass Zachary T. , Onken Michael D. , Lee Ryan S. , Bowcock Anne M. , Harbour J. William
Published: April 2023

PDF file - 371K
Supplementary Figure 5 from Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma
Authors: Akter Jesmin , Takatori Atsushi , Hossain Md. Shamim , Ozaki Toshinori , Nakazawa Atsuko , Ohira Miki , Suenaga Yusuke , Nakagawara Akira
Published: April 2023

PDF file - 556KB
Supplementary Figure 4 from Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma
Authors: Akter Jesmin , Takatori Atsushi , Hossain Md. Shamim , Ozaki Toshinori , Nakazawa Atsuko , Ohira Miki , Suenaga Yusuke , Nakagawara Akira
Published: April 2023

PDF file - 44KB
Supplementary Figure 2 from Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma
Authors: Akter Jesmin , Takatori Atsushi , Hossain Md. Shamim , Ozaki Toshinori , Nakazawa Atsuko , Ohira Miki , Suenaga Yusuke , Nakagawara Akira
Published: April 2023

PDF file - 30KB
Supplementary Table 2 from Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
Authors: Tsai Ping-Chiao , Hernandez-Ilizaliturri Francisco J. , Bangia Naveen , Olejniczak Scott H. , Czuczman Myron S.
Published: April 2023

PDF file - 33K
Supplementary Table 1 from Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
Authors: Tsai Ping-Chiao , Hernandez-Ilizaliturri Francisco J. , Bangia Naveen , Olejniczak Scott H. , Czuczman Myron S.
Published: April 2023

PDF file - 54K
Supplementary Figure 6 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
Authors: Petrich Adam M. , Leshchenko Violetta , Kuo Pei-Yu , Xia Bing , Thirukonda Venu K. , Ulahannan Netha , Gordon Shanisha , Fazzari Melissa J. , Ye B. Hilda , Sparano Joseph A. , Parekh Samir
Published: April 2023

PDF file - 24K, Vinblastine does not synergize with Rapamycin in SU-DHL 4 cell line. A-B. Approximately 106 cells/ml of SUDHL-4 and SUDHL-6 were treated with Rapamycin, Vinblastine, and the combination of both drugs (all doses lower than IC50 for each drug), for 48h. Viability was assessed by a ﬂuorometric resazurin reduction assay. Each experiment was performed in octuplicate, and repeated twice. Shown here are representative results. C-D. Combination indices for the effects of combination of Rapamycin and Vinblastine on viability, as determined using the Chou-Talalay equation, are shown.
Supplementary Figure 2 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
Authors: Petrich Adam M. , Leshchenko Violetta , Kuo Pei-Yu , Xia Bing , Thirukonda Venu K. , Ulahannan Netha , Gordon Shanisha , Fazzari Melissa J. , Ye B. Hilda , Sparano Joseph A. , Parekh Samir
Published: April 2023

PDF file - 96K, A. Approximately 106 cells/ml of two Rapamycin-sensitive cell lines (SUDHL-6 and WSU-NHL) and two Rapamycin-resistant cell lines (SUDHL-4 and OCI-Ly19) DLBCL cells were treated with Rapamycin, an Akt inhibitor, either Nelfinavir or MK-2206, and the combination of Rapamycin and an Akt inhibitor, for 48h. Viability was assessed by a ﬂuorometric resazurin reduction assay. Each experiment was performed in octuplicate, and repeated twice. Shown here are representative results for the Rapamycin-sensitive SUDHL-6 cell line after 48 hours of treatment with Rapamycin (Rapa), Nelfinavir (Nelf), and the combination. B. Rapamycin-resistant cell lines (SUDHL-4 and OCI-Ly19), and Rapamycin-sensitive cell lines (SUDHL-6 and WSU-NHL) were treated with the combination of Rapamycin and MK-2206 for 48h, as described above. Combination indices for the effects on viability, as determined using the Chou-Talalay equation, are shown. C-F. DLBCL cell lines were treated for 12 hours with Rapamycin and MK-2206 (C and E), and Rapamycin and Nelfinavir (D and F), and then analyzed by flow cytometry after staining with propidium iodide. Each experiment was repeated twice under independent conditions, with representative results shown. Cell cycle progression, as represented by proportion of cells in S-phase, in the Rapamycin-resistant cell line OCI-Ly19 (C and D), and the Rapamycin-sensitive cell line SUDHL-6 (E and F) are shown.
Supplementary Figure 1 from Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Authors: Pander Jan , Heusinkveld Moniek , van der Straaten Tahar , Jordanova Ekaterina S. , Baak-Pablo Renée , Gelderblom Hans , Morreau Hans , van der Burg Sjoerd H. , Guchelaar Henk-Jan , van Hall Thorbald
Published: April 2023

PDF file - 304K
Supplementary Tables 1-2 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
Authors: Asnaghi Laura , Ebrahimi Katayoon B. , Schreck Karisa C. , Bar Eli E. , Coonfield Michael L. , Bell W. Robert , Handa James , Merbs Shannath L. , Harbour J. William , Eberhart Charles G.
Published: April 2023

PDF file - 36K
Supplementary Figure 3A from Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Authors: Inoue Kinya , Torimura Takuji , Nakamura Toru , Iwamoto Hideki , Masuda Hiroshi , Abe Mitsuhiko , Hashimoto Osamu , Koga Hironori , Ueno Takato , Yano Hirohisa , Sata Michio
Published: April 2023

PDF file, 143KB, Vandetanib inhibits tumor growth in the liver of nude mice.
Supplementary Figure 5 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
Authors: Asnaghi Laura , Ebrahimi Katayoon B. , Schreck Karisa C. , Bar Eli E. , Coonfield Michael L. , Bell W. Robert , Handa James , Merbs Shannath L. , Harbour J. William , Eberhart Charles G.
Published: April 2023

PDF file - 369K
Supplementary Figure 1 from Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Authors: Inoue Kinya , Torimura Takuji , Nakamura Toru , Iwamoto Hideki , Masuda Hiroshi , Abe Mitsuhiko , Hashimoto Osamu , Koga Hironori , Ueno Takato , Yano Hirohisa , Sata Michio
Published: April 2023

PDF file, 128KB, Inhibitory effect of vandetanib on cell proliferation.
Supplementary Figure 1-2 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
Authors: Asnaghi Laura , Ebrahimi Katayoon B. , Schreck Karisa C. , Bar Eli E. , Coonfield Michael L. , Bell W. Robert , Handa James , Merbs Shannath L. , Harbour J. William , Eberhart Charles G.
Published: April 2023

PDF file - 1.5MB
Supplementary Tables 1 - 12, Figures 1 - 7 from Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
Authors: Lachenmayer Anja , Alsinet Clara , Savic Radoslav , Cabellos Laia , Toffanin Sara , Hoshida Yujin , Villanueva Augusto , Minguez Beatriz , Newell Philippa , Tsai Hung-Wen , Barretina Jordi , Thung Swan , Ward Stephen C. , Bruix Jordi , Mazzaferro Vincenzo , Schwartz Myron , Friedman Scott L. , Llovet Josep M.
Published: April 2023

PDF file, 10.8MB, Supplementary Table 1: Clinical characteristics of human hepatocellular carcinoma samples. Supplementary Table 2: Clinical Characteristics of 5 public HCC datasets. Supplementary Table 3: Wnt-pathway mRNA list: 210 Wnt-related genes from the literature. Supplementary Table 4: Wnt-pathway miRNA list: 49 Wnt-related miRNAs from the literature. Supplementary Table 5: Significantly differentially expressed Wnt-related genes in CTNNB1- and Wnt-TGF_-class samples of the training set. Supplementary Table 6: Summary of dysregulated CTNNB1- and Wnt-TGF_-Wnt-genes according to their cellular localization and their known or suspected function. Supplementary Table 7: Expression of known liver-related Wnt-target-genes. Supplementary Table 8: Correlation of Wnt-related transcription factors to Wnt-target-genes in the training set. Supplementary Table 9: Frequency _catenin IHC positive samples and CTNNB1 mutations Wnt-related and non-Wnt-related subclasses of HCC in the in training (T) and validation (V) sets. Supplementary Table 10: Differentially expressed Wnt-related-miRNAs in 89 HCC samples of the training set. Supplementary Table 11: Enrichment of samples identified by CTNNB1-, Wnt-TGF__ WntGenes- and CTNNB1-mutation-signature in CTNNB1 and Wnt-TGF_ subclasses in 5 independent datasets (Fisher's Exact Test). Supplementary Table 12: 21 Liver Cancer cell lines analyzed by GSEA for gene expression profiles similar to either CTNNB1 or Wnt-TGF_ class. Supplementary Figure 1: Differential Expression of Wnt-pathway mRNAs in the CTNNB1- and Wnt-TGF Beta-classes in the training set. Supplementary Figure 2: Differential Expression of Wnt-pathway-miRNAs in the CTNNB1- and Wnt-TGF Beta-classes in the training set. Supplementary Figure 3: Validation of CTNNB1- and Wnt-TGF Beta-specific Wnt-related mRNA profiles and mutation-status in 5 public HCC datasets. Supplementary Figure 4: Validation of the mutation signature in an independent cohort of HCC. Supplementary Figure 5: Correlation of gene expression data from 21 different liver cancer cell lines with CTNNB1 and Wnt-TGF Beta class signatures by GSEA. Supplementary Figure 6: Baseline luciferase levels in Wnt reporter liver cancer cells stably transduced with TCF/LEF luciferase reporter. Supplementary Figure 7: Sorafenib decreases beta-catenin protein levels in 4 liver cancer cell lines.
Supplementary Figure 3 from Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Authors: Wicki Andreas , Rochlitz Christoph , Orleth Annette , Ritschard Reto , Albrecht Imke , Herrmann Richard , Christofori Gerhard , Mamot Christoph
Published: April 2023

PDF file - 85K, Biodistribution of anti-VEGFR2 Immunliposomes Analysis of tissue samples showed a non-significant trend to a higher concentration of ILs in parenchymal organs (lung, liver and spleen) but not in the tumor (A and B). Rip1Tag2 mice were treated with liposomes (black columns) and anti-VEGFR2 ILs (dotted columns), which were labelled with 3H-cholesteryl hexadecylether, injected via tail vein at a dose of 31.25 �mol phospholipid/kg mouse (cohorts of 4-6 mice x time point and treatment). At 24 (A) or 48 (B) hours mice and 3H-cholesteryl hexadecyl concentration were determined. The final distribution was expressed as % of injected dose (ID)/g tissue and % ID/concentration in blood circulation. Columns: mean; bars: SD (non-significant by Dunn's multiple comparison test).
Supplementary Figure 2 from Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Authors: Brunsvig Paal Fr. , Kyte Jon Amund , Kersten Christian , Sundstrøm Stein , Møller Mona , Nyakas Marta , Hansen Gaute L. , Gaudernack Gustav , Aamdal Steinar
Published: April 2023

PDF file - 2567KB
Supplementary Figure 1 from Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Authors: Wicki Andreas , Rochlitz Christoph , Orleth Annette , Ritschard Reto , Albrecht Imke , Herrmann Richard , Christofori Gerhard , Mamot Christoph
Published: April 2023

PDF file - 762K, (A) Immunoliposomes bind specifically to their targets in vitro. Specific binding capacity was evaluated in MDA-MB468, a human breast cancer cell line, with endogenous overexpession of EGFR. Cells were incubated with DiIC18(3)- DS-labeled immunoliposomes containing DC101-Fab'(anti-mVEGFR2), C225-Fab' (anti-hEGFR) or with control liposomes, where the Fab' regions of the antibodies were omitted. A shift of two log was detected in anti-hEGFR-ILs, while the anti-mVEGFR2-ILs were comparable with the DiIC18(3)- DS-labeled liposomes. This confirmed target specificity. (1) filled black histogram: untreated MDA-MB468 cells; (2) dark grey open histogram: control non-targeted DiIC18(3)- DS-labeled liposomes; (3) light grey open histogram: anti-VEGFR2-ILs; (4) filled light grey histogram: anti-EGFR-ILs. (B) Anti-VEGFR2-ILs specifically bind to VEGFR2 positive cells in vivo (immunofluorescence). Vessel in the endocrine pancreas of a Rip1Tag2 mouse treated with anti-VEGFR2 ILs-dox or PLD. The Fab` fragment of DC101, a rat antibody, was coupled to the liposomal surface. VEGFR2 was detected with a goat-derived antibody. Detection with anti-rat-Fab`-FITC labeled antibody showed specific binding of VEGFR2 in the tumor tissue in anti-VEGFR2-ILs treated mice, but not in PLD treated mice. Red = staining for anti-VEGFR2, green = staining for anti-rat-Fab', blue = DAPI. (C) Anti-VEGFR2-ILs specifically bind to CD31-positive tumor-associated vascular cells in vivo (FACS). For uptake studies in vivo, liposomes were labeled with 0.1-0.3 mol% DiIC18(3)-DS (DiI-Ls). 12 weeks old Rip1Tag2 mice were injected i.v. with DiI-ILs or anti-VEGFR2 liposomes labeled with DiI (anti-VEGFR2-DiI-ILs). 36h after injection mice were sacrificed and a single cell suspension of pancreatic tumors was prepared by Dispase digestion. For subsequent FACS analysis cells were stained with PerCp-CD45 and APC-CD31 Ab. The CD31 positive cells were gated and the incorporated DiI was measured. Mice injected with anti-VEGFR2-DiI-ILs showed an increase in DiI uptake compared to control mice (70.1% and 24.8%, respectively). The mean fluorescence augmented from 30.4 to 61.1 in anti-VEGFR2-DiI-ILs treated mice.
Supplementary Figure Legends 1-8 from Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival
Authors: Gubanova Evgenia , Brown Brandee , Ivanov Sergei V. , Helleday Thomas , Mills Gordon B. , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

PDF file - 69K
Supplementary Table 4 from Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment
Authors: Vermaat Joost S. , Nijman Isaac J. , Koudijs Marco J. , Gerritse Frank L. , Scherer Stefan J. , Mokry Michal , Roessingh Wijnand M. , Lansu Nico , de Bruijn Ewart , van Hillegersberg Richard , van Diest Paul J. , Cuppen Edwin , Voest Emile E.
Published: April 2023

PDF file - 223K, Sanger Verification.
Supplementary Table 3 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Authors: Punnoose Elizabeth A. , Atwal Siminder , Liu Weiqun , Raja Rajiv , Fine Bernard M. , Hughes Brett G.M. , Hicks Rodney J. , Hampton Garret M. , Amler Lukas C. , Pirzkall Andrea , Lackner Mark R.
Published: April 2023

PDF file - 158K
Supplementary Table 1 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Authors: Punnoose Elizabeth A. , Atwal Siminder , Liu Weiqun , Raja Rajiv , Fine Bernard M. , Hughes Brett G.M. , Hicks Rodney J. , Hampton Garret M. , Amler Lukas C. , Pirzkall Andrea , Lackner Mark R.
Published: April 2023

PDF file - 309K
Supplementary Figure 3 from Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival
Authors: Gubanova Evgenia , Brown Brandee , Ivanov Sergei V. , Helleday Thomas , Mills Gordon B. , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

PDF file - 1.5MB
Supplementary Figure 1 from Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival
Authors: Gubanova Evgenia , Brown Brandee , Ivanov Sergei V. , Helleday Thomas , Mills Gordon B. , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

PDF file - 1.9MB
Supplementary Data from Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Authors: Rosell Rafael , Molina Miguel Angel , Costa Carlota , Simonetti Sara , Gimenez-Capitan Ana , Bertran-Alamillo Jordi , Mayo Clara , Moran Teresa , Mendez Pedro , Cardenal Felipe , Isla Dolores , Provencio Mariano , Cobo Manuel , Insa Amelia , Garcia-Campelo Rosario , Reguart Noemi , Majem Margarita , Viteri Santiago , Carcereny Enric , Porta Ruth , Massuti Bartomeu , Queralt Cristina , de Aguirre Itziar , Sanchez Jose Miguel , Sanchez-Ronco Maria , Mate Jose Luis , Ariza Aurelio , Benlloch Susana , Sanchez Jose Javier , Bivona Trever G , Sawyers Charles L , Taron Miquel
Published: April 2023

Supplementary Figures S1-S3; Supplementary Tables S1-S14.
Related Articles from Micromanaging the Classification of Colon Cancer: The Role of the microRNAome
Authors: Vilar Eduardo , Tabernero Josep , Gruber Stephen B.
Published: April 2023

Related Articles from Micromanaging the Classification of Colon Cancer: The Role of the microRNAome
Supplementary Data from Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors
Authors: Bagatell R. , Herzog C.E. , Trippett T.M , Grippo J.F. , Cirrincione-Dall G. , Fox E. , Macy M. , Bish J. , Whitcomb P. , Aikin A. , Wright G. , Yurasov S. , Balis F.M. , Gore L.
Published: April 2023

Supplementary Figure S1; Supplementary Table S1.
Supplementary Data from Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Leonhardt Payton , Ladanyi Andras , Yamada S. Diane , Montag Anthony , Im Hae Kyung , Jagadeeswaran Sujatha , Shaw David E. , Mazar Andrew P. , Lengyel Ernst
Published: April 2023

Supplementary Figures S1-S3; Supplementary Table S1.
Supplementary Figure Legend from Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Authors: Oxnard Geoffrey R. , Janjigian Yelena Y. , Arcila Maria E. , Sima Camelia S. , Kass Samantha L. , Riely Gregory J. , Pao William , Kris Mark G. , Ladanyi Marc , Azzoli Christopher G. , Miller Vincent A.
Published: April 2023

PDF file - 44K
Supplementary Legends for Figure 1 and Tables 1-4 from Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Authors: Barrow Hannah , Guo Xiuli , Wandall Hans H. , Pedersen Johannes W. , Fu Bo , Zhao Qicheng , Chen Chen , Rhodes Jonathan M. , Yu Lu-Gang
Published: April 2023

PDF file - 71K
Supplementary Figure 1, Tables 1-4 from Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Authors: Barrow Hannah , Guo Xiuli , Wandall Hans H. , Pedersen Johannes W. , Fu Bo , Zhao Qicheng , Chen Chen , Rhodes Jonathan M. , Yu Lu-Gang
Published: April 2023

PDF file - 146K
Supplementary Methods, Figure Legends 1-8 from Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
Authors: Höglund Andreas , Nilsson Lisa M. , Muralidharan Somsundar Veppil , Hasvold Lisa A. , Merta Philip , Rudelius Martina , Nikolova Viktoriya , Keller Ulrich , Nilsson Jonas A.
Published: April 2023

PDF file - 116K
Supplementary Data from Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors
Authors: Khan Mohid S. , Tsigani Theodora , Rashid Mohammed , Rabouhans Jeremy S. , Yu Dominic , Luong Tu Vinh , Caplin Martyn , Meyer Tim
Published: April 2023

Supplementary Figures S1-S4; Supplementary Table S1.
Supplementary Data from Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy
Authors: Li Long Shan , Bey Erik A. , Dong Ying , Meng Jieru , Patra Biswanath , Yan Jingsheng , Xie Xian-Jin , Brekken Rolf A. , Barnett Carlton C. , Bornmann William G. , Gao Jinming , Boothman David A.
Published: April 2023

Supplementary Figures S1-S3; Supplementary Table S1.
Supplementary Tables 1 - 4 from SSBP2 Variants Are Associated with Survival in Glioblastoma Patients
Authors: Xiao Yuanyuan , Decker Paul A. , Rice Terri , McCoy Lucie S. , Smirnov Ivan , Patoka Joseph S. , Hansen Helen M. , Wiemels Joe L. , Tihan Tarik , Prados Michael D. , Chang Susan M. , Berger Mitchel S. , Kosel Matthew L. , Fridley Brooke L. , Lachance Daniel H. , O'Neill Brian Patrick , Buckner Jan C. , Thompson Reid C. , Nabors Louis Burt , Olson Jeffrey J. , Brem Steve , Madden Melissa H. , Browning James E. , Wiencke John K. , Egan Kathleen M. , Jenkins Robert B. , Wrensch Margaret R.
Published: April 2023

PDF file, 406KB, Supplementary Table 1.115 TCGA SOC sample IDs used in the validation phase.; Supplementary Table 2. Proportionality tests based on the scaled Schoenfeld residules for the SNP effect in the log-additive Cox Proportional Hazards model adjusted for age and sex.; Supplementary Table 3. Validation of survival association with three SNPs in glioblastoma multiforme patients from three independent studies (Mayo Clinic10, GliomaSE11 and The Cancer Genome Atlas (TCGA17); Supplementary Table 4. Imputation analyiss of SSBP2 region:chr5: 80,680,000 -- 80,980,000, University of California, San Francisco Adult Glioma Study (AGS), Mayo Clinic, and The MACH, Hapmap 2, human genome build 18, 3 sites (University of California, San Francisco, Mayo Clinic and The Cancer Genome Atlas).
Supplementary Figure Legend 1 from Glioblastoma Stem–like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration
Authors: Schulte Alexander , Günther Hauke S. , Martens Tobias , Zapf Svenja , Riethdorf Sabine , Wülfing Clemens , Stoupiec Malgorzata , Westphal Manfred , Lamszus Katrin
Published: April 2023

PDF file - 42K
Supplementary Figure 2 from Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell
Authors: Tanaka Makito , Butler Marcus O. , Ansén Sascha , Imataki Osamu , Berezovskaya Alla , Nadler Lee M. , Hirano Naoto
Published: April 2023

PDF file - 7.46MB
Supplementary Figure 1 from Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell
Authors: Tanaka Makito , Butler Marcus O. , Ansén Sascha , Imataki Osamu , Berezovskaya Alla , Nadler Lee M. , Hirano Naoto
Published: April 2023

PDF file - 610K
Supplementary Table 2 from Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Authors: Sihto Harri , Böhling Tom , Kavola Heli , Koljonen Virve , Salmi Marko , Jalkanen Sirpa , Joensuu Heikki
Published: April 2023

PDF file, 24KB, Associations of tumor infiltrating CD16+ natural killer cells, CD68+ macrophages, and CD163+ macrophages with patient and tumor characteristics.
Supplementary Figures 1-3, Table 1 from Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097
Authors: Wu Jianmei , LoRusso Patricia M. , Matherly Larry H. , Li Jing
Published: April 2023

PDF file - 149K
Supplementary Table 5 from Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Authors: Donahue Timothy R. , Tran Linh M. , Hill Reginald , Li Yunfeng , Kovochich Anne , Calvopina Joseph H. , Patel Sanjeet G. , Wu Nanping , Hindoyan Antreas , Farrell James J. , Li Xinmin , Dawson David W. , Wu Hong
Published: April 2023

PDF file - 217K